Advertisement

Clinical chemistry in women treated with levonorgestrel implants (NORPLANT™∗∗NORPLANT™is the Population Council's trademark for subdermal implants containing levonorgestrel.) or a TCu 200 IUD

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Two groups of implant users and two groups of IUD users participated in the study at different times. In the first groups, fractionation of lipoproteins was performed on serum samples from 28 subjects who had used the implants for 37 months and from 26 subjects who had used the Copper TCu 200 for 30 months. Users of the implants had significantly lower levels of total cholesterol, triglycerides and LDL-cholesterol than users of the IUDs. HDL-cholesterol levels were not different between the groups. In the other groups of women, general chemistries and selected hormone assays were carried out on samples from 30 subjects who had used implants for 51 months and from 24 subjects who had used the TCu 200 IUDs for 43 months. The parameters studied were the SMA-12 chemistry group profile, estradiol, cortisol, testosterone, triiodothyronine, thyroxine and thyroid stimulating hormone. In the implant group, mean serum glucose levels were statistically significantly elevated and inorganic phosphorus levels were significantly reduced as compared to the IUD group. In both cases all individual measurements were within the normal range for the population. Testosterone and triiodothyronine levels in the implant group were significantly lower than in the IUD group, but no individual values were outside the normal range for the population. Mean values for all other parameters were not significantly different between the groups.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. ICCR Implant Study I.
        Contraception. 1978; 18: 315
      2. ICCR Implant Study II.
        Contraception. 1978; 18: 335
        • Diaz S.
        • Pavez M.
        • Robertson D.N.
        • Croxatto H.B.
        A three-year clinical trial with levonorgestrel Silastic implants.
        Contraception. 1979; 19: 557
        • Sivin I.
        • Robertson D.N.
        • Stern J.
        • Croxatto H.B.
        • Diaz S.
        • Coutinho E.
        • daSilva A.R.
        • Sanchez F.
        • Alvarez Faundes A.
        • McDonald O.
        • Holma P.
        • Nielsen N.C.
        • Osler M.
        • Nash H.A.
        NORPLANT: Reversible implant contraception.
        Studies in Family Planning. 1980; 11: 227
        • Diaz S.
        • Pavez M.
        • Miranda P.
        • Robertson D.N.
        • Sivin I.
        • Croxatto H.B.
        A five-year clinical trial of levonorgestrel Silastic implants (NORPLANT).
        Contraception. 1982; 25: 447
        • Weiner E.
        • Johansson E.D.B.
        Plasma levels of d-norgestrel, estradiol and progesterone during treatment with Silastic implants containing d-norgestrel.
        Contraception. 1976; 14: 81
        • Croxatto H.B.
        • Diaz S.
        • Pavez M.
        Clinical chemistry in women treated with progestogen implants.
        Contraception. 1978; 18: 441
        • Spellacy W.N.
        • Buhi W.C.
        • Birk S.A.
        The effects of norgestrel on carbohydrate and lipid metabolism over one year.
        Am. J. Obstet. Gynecol. 1975; 125: 984
        • Vongvinyoutragan S.
        • Matangkasombuit O.
        • Poshyachinda V.
        • Dusitsin N.
        • Tankeyoon M.
        • Israngkun P.
        • Chaudhury R.R.
        The effect of dnorgestrel, 30 micrograms, on the oral glucose tolerance test, including insulin levels, in Thai women.
        Fertil. Steril. 1976; 27: 523
        • Foss G.L.
        • Holter J.B.
        • Lewis F.J.W.
        Effects of long-term microdose of norgestrel on glucose tolerance and serum transaminase levels.
        J. Reprod. Fert. 1970; 23: 185
        • Boyns D.R.
        • Crossly J.N.
        • Abrams M.E.
        • Jarrett R.J.
        • Keen H.
        Oral glucose tolerance and related factors in a normal population sample.
        Br. Med. J. 1969; 1: 595
        • Kammen E.Van
        • Thijssen J.H.H.
        • Rademaker B.
        • Schwarz F.
        The influence of hormonal contraceptives on sex hormone binding globulin (SHBG) capacity.
        Contraception. 1975; 11: 53
        • Victor A.
        • Weiner E.
        • Johansson E.D.B.
        Sex hormone binding globulin: The carrier protein for d-norgestrel.
        J Clin Endocrinol Metab. 1976; 43: 244
        • Sisson J.C.
        Principles of and pitfalls in, thyroid function tests.
        J Nuclear Med. 1965; 6: 853